The rare disease bile duct cancer is set to be carved up by genetic subtype, and will see two targeted treatments filed soon.
A surprisingly successful study of Opdivo and Yervoy suggests that the enrolment of co-called hyperprogressors could have scuppered other trials.
Roche’s Imvigor-130 study supports Tecentriq’s continued use in urothelial bladder cancer – up to a point.
Lynparza looks set to add a third tumour type to its label, strengthening the grip of Astrazeneca and Merck & Co on the Parp inhibitor market.
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.
The triple-negative breast cancer trial backs neoadjuvant Keytruda, and the good news for Merck is that an adjuvant benefit cannot be ruled out either.
As selpercatinib confirms its activity in thyroid cancer, Eli Lilly gears up to prove the Ret inhibitor’s potential in larger trials.
Amgen’s AMG 510 disappoints Kras bulls, showing just two new partial responses, in colorectal and appendiceal tumours.
The Prima trial delivers a convincing win for Glaxosmithkline’s Parp inhibitor Zejula, which looks to have a good chance of winning a broader label in ovarian cancer.